Papers Published

  1. Bartlett JA, Berry P, Bockman W, Johnson J, Quinn J, Graham S, DeMasi R, Alexander WJ. A placebo controlled trial of ranitidine in patients with early HIV infection. J Infect Dis. 177:231-234, 1998.
  2. Bartlett JA, DeMasi R, Dawson D, Hill A. Variability in the repeated consecutive measurements of plasma HIV RNA in persons on stable nucleoside reverse transcriptase inhibitor or no therapy. J Infect Dis. 178:1803-1805, 1998.
  3. Bartlett JA, Wasserman S, Hicks C, Dodge R, Weinhold K, Tacket C, Ketter N, Wittek A, Palker T, Haynes BF and the DATRI 010 Study Group. Safety and immunogenicity of C4V3 polyvalent synthetic peptides in HIV-infected HLA B7 positive subjects with CD4 cells >500/mm3. AIDS. 12:1291-1330, 1998.
  4. Bartlett JA, Berend C, Petroni G, Ottinger J, Tyler D, Pettinelli C, Weinhold K. Co-administration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed Stage 2 HIV infection: Results of ACTG protocol 042. J Infect Dis. 178:1170-1173, 1998.
  5. Haynes BF, Hale LP, Weinhold KJ, Patel DD, Liao H-X, Bressler PB, Jones DM, Demarest JF, Gebhard-Mitchell K, Haase AT, Bartlett JA. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Investig; in press, 1998.
  6. Bartlett JA, Hullette C. Central nervous system pneumocysostis in the acquired immune deficiency syndrome. Clinical Infectious Diseases. 25:82-85, 1997.
  7. Bartlett JA, Berry P, Bockman W, Johnson J, Quinn J, Graham S, DeMasi R, Alexander WJ. A placebo controlled trial of ranitidine in patients with early HIV infection. Journal of Infectious Diseases. 177:231-234, 1997.
  8. Staszewski S, Hill AM, Bartlett JA, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS. 11:477-483, 1997.
  9. Ferrari G, Berend C, Ottinger J, Dodge R,Bartlett J, Toso J, Moody D, Tartaglia J, Cox W, Paoletti E, Weinhold K. Replication -defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiemcy virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. Blood, (90) 6; 2406-2416, 1997.
  10. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA and Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial. Journal of Immune Deficiency Syndromes and Human Retrovirology. 16:100-107, 1997.
  11. Bartlett JA, Berend C, Ottinger J, Tyler D, Petroni G, Petinelli C, Weinhold KJ. Co-administration of zidovudine and interleukin-2 increases absolute CD4+ cells in subjects with Walter Reed stage 2 HIV infection: Results of ACTG protocol 042. Submitted to Journal of Infectious Diseases.
  12. Bartlett JA, Wasserman S, Hicks C, Dodge R, Weinhold K, Tacket C, Ketter N, Wittek A, Palker T, Haynes BF and the DATRI 010 Study Group. Safety and immunogenicity of C4V3 polyvalent synthetic peptides in HIV-infected HLA B7 positive subjects with CD4 cells > 500/mm3. Submitted to Journal of Infectious Diseases.
  13. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Accepted in the International Journal of STD's and AIDS.
  14. Bartlett JA. Editor, Caring for Persons with HIV infection. Clean Data Publishing Co., 1995.
  15. Graham CS, Graham BG, Bartlett JA, Heald AE, Schiffman SS. Taste and smell losses in HIV infected patients. Physiology & Behavior. 58:287-294, 1995.
  16. Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis G, Lalezari J, Bartlett JA, Steigbigel RT, Cohen J, Novak R, McMahon D, Fauci AS. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects down regulation of viral replication in lymphoid tissue. Proceedings of the National Academy of Sciences USA. 92:6017-6021, 1995.
  17. Ferrari G, King K, Rathbun K, Packard M, Bartlett JA, Bolognesi D, Weinhold K. Interleukin 7 (IL-7) enhancement of antigen-driven activation/expansion of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte precursors (CTLp). Clinical and Experimental Immunology 1995;101:239-248.
  18. Jacobson MA, DeGruttola V, Reddy M, Ardvino J-M, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, Soiero R, Volberding P. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS 1995;9:727-734.
  19. Bartlett, JA. Antiretroviral therapy. Caring for Persons with HIV Infection; edited by John A. Bartlett: Clean Data Publishing Co., 1995.
  20. Bartlett JA. Chronic management and counseling for persons with HIV infection. Cecil's Textbook of Medicine; edited by Claude Bennett. 1994.
  21. Volbering P, Lagakos S, Grimes J, Stein D, Balfour H, Dolin R, Bartlett J, Hirsch M, Phair J, Mitsuyasu R, Fischl M, Soeir R and the AIDS Clinical Trials Group. The duration of zidovudine benefit and effects of delayed initiation in persons with asymptomatic HIV infection: Prolonged evaluation of ACTG protocol 019 subjects. JAMA 1994;272:437-442.
  22. Chin-Ho C, Weinhold K, Bartlett J, MacDougall M and Greenberg ML: CD8+ T-lymphocytes from asymptomatic HIV-1 infected individuals suppress TAT-mediated HIV-1 LTR transcription. AIDS Research & Human Retroviruses. 1993;9:1079-1086.
  23. Bartlett JA, Wasserman S, Hicks C, Dodge R, Weinhold K, Tacket C, Ketter N, Wittek A, Palker T, Haynes BF and the DATRI 010 Study Group. Safety and immunogenicity of C4V3 polyvalent synthetic peptides in HIV-infected HLA B7 positive subjects with CD4 cells > 500/mm3. Submitted to Journal of Infectious Diseases.
  24. Bartlett JA, Berend C, Ottinger J, Tyler D, Petroni G, Petinelli C, Weinhold KJ. Co-administration of zidovudine and interleukin-2 increases absolute CD4+ cells in subjects with Walter Reed stage 2 HIV infection: Results of ACTG protocol 042. Submitted to Journal of Infectious Diseases.

©2013 Duke Global Health Institute | Contact Us | Employment | Make a Gift | Duke University | Duke Medicine | Interdisciplinary Studies